Adalimumab and Infliximab in Crohn`s disease-real life data from a national retrospective cohort study

Current Health Sciences Journal

Carmen Preda ; Larisa Fulger ; Liana Gheorghe ; C. Gheorghe ; A. Goldis ; Anca Trifan ; M. Tantau ; Alina Tantau ; L. Negreanu ; M. Manuc ; Cristina Cijevschi-Prelipcean ; R. Iacob ; C. TIERANU ; Corina Meianu ; M. DICULESCU

关键词: Adalimumab;    Infliximab;    Crohn`s disease;   

学科分类：医学（综合）

来源: Universitatea de Medicina si Farmacie din Craiova / University of Medicine and Pharmacy

【 摘 要 】

Aim: to compare the efficacy and safety of Adalimumab(ADA) and Infliximab(IFX), in a large Romanian population and to identify predictors of response. Methods We performed a national retrospective cohort study including 265 patients (136 ADA, 129 IFX) between 2008-2014. Binary logistic regression was performed with the statistical program Minitab. Results: Patients were half women, with a median age of 36, a median disease duration of 2.5 years, 80% received Azathioprine. Mean therapy duration was 20 months in ADA group and 36 months in IFX group. Complete response to Adalimumab respectivelyInfliximab was recorded in 77%vs.65%, secondary loss of response in 18%vs.28%, statistically comparable. We failed to identify predictors of response.In 79.2%of patients with secondary loss of response to ADA, the dose was escalated, 12.5% were switched to Infliximab. In 70%of patients that lost response to IFX, the dose was increased, 30% were switched to Adalimumab. Conclusions: Adalimumab and Infliximab have similar efficacy, with a complete response rate of~70%. In case of secondary loss of response to IFX, the best solution is to switch to ADA, with 83% response rate, while in case of secondary loss of response to ADA, increasing the dose leads to 84 % response rate.

【 授权许可】

Unknown